Skip to main content

Table 3 Sensitivities and specificities based on fixed PC-594 positivity rates in low-risk subjects

From: Metabolic system alterations in pancreatic cancer patient serum: potential for early detection

% Positivity < age 50 (specificity, 95% CI) USA PC % Sensitivity (95% CI) % Specificity* (95% CI)
USA Control 1 by age
50-59 60-69 70-80 USA control 2
0.5 (99.5, 98–100) 7 (0.4-36) 100 (97–100) 99 (96–100) 100 (97–100) 100 (89–100)
1.0 (99.0, 97–100) 21 (6–52) 99 (95–100) 95 (91–98) 97 (93–99) 100 (89–100)
2.5 (97.5, 95–99) 64 (36–86) 97 (93–99) 90 (85–94) 93 (88–96) 95 (82–99)
5.0 (95.0, 92–97) 87 (56–98) 94 (90–97) 84 (78–88) 77 (70–82) 95 (82–99)
10.0 (90.0, 87–93) 100 (73–100) 90 (85–94) 74 (68–80) 67 (60–73) 83 (67–92)
  1. *assuming no PC among reference subjects.